5-(4-氯苯基)-2-甲基-2H-吡唑-3-羧酸 | 1015868-48-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(4-氯苯基)-2-甲基-2H-吡唑-3-羧酸
• 英文名称: 1-methyl-3-(4-chlorophenyl)-1H-pyrazole-5-carboxylic acid
• 英文别名: 3-(4-chlorophenyl)-1-methyl-1H-pyrazole-5-carboxylic acid；5-(4-chlorophenyl)-2-methylpyrazole-3-carboxylic acid
• CAS: 1015868-48-0
• 化学式: C₁₁H₉ClN₂O₂
• mdl: MFCD08446011
• 分子量: 236.658
• InChiKey: JNOADCITUCNMIN-UHFFFAOYSA-N

物化性质

• 沸点：
  443.7±35.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-(4-氯苯基)-2-甲基-2H-吡唑-3-羧酸 在 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-methyl-3-(4-chlorophenyl)-1H-pyrazole-5-carbonyl chloride
  参考文献：
  名称：

  Pyrazole derivatives as inhibitors of arachidonic acid-induced platelet aggregation

  摘要：

  Antiplatelet drugs are promising therapeutics to intervene with platelet aggregation in arterial thrombosis, most prominently in myocardial infarction and ischemic stroke. Here, we describe the synthesis and structure activity relationships of potent inhibitors of platelet aggregation based on the 1,5-diarylpyrazol-3-carboxamide scaffold. Analogs from this series demonstrated potent anti-aggregatmy activities against arachidonic acid-induced platelet aggregation, as measured by turbidimetric method of Born. 1,5-Diarylpyrazole-3-carboxamides obtained with small-basic amines (7, 8, 50, 51, 61, 62) displayed the strongest activity with IC50 values in low nanomolar range (5.7-83 nM). On the basis of their high potency in cellular environment, these straightforward pyrazole derivatives may possess potential in the design of more potent compounds for intervention with cardiovascular diseases. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.048
• 作为产物：
  描述：

  methyl 3-(4-chlorophenyl)-1H-pyrazole-5-carboxylate 在 水 、 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-(4-氯苯基)-2-甲基-2H-吡唑-3-羧酸
  参考文献：
  名称：

  Pyrazole derivatives as inhibitors of arachidonic acid-induced platelet aggregation

  摘要：

  Antiplatelet drugs are promising therapeutics to intervene with platelet aggregation in arterial thrombosis, most prominently in myocardial infarction and ischemic stroke. Here, we describe the synthesis and structure activity relationships of potent inhibitors of platelet aggregation based on the 1,5-diarylpyrazol-3-carboxamide scaffold. Analogs from this series demonstrated potent anti-aggregatmy activities against arachidonic acid-induced platelet aggregation, as measured by turbidimetric method of Born. 1,5-Diarylpyrazole-3-carboxamides obtained with small-basic amines (7, 8, 50, 51, 61, 62) displayed the strongest activity with IC50 values in low nanomolar range (5.7-83 nM). On the basis of their high potency in cellular environment, these straightforward pyrazole derivatives may possess potential in the design of more potent compounds for intervention with cardiovascular diseases. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.048

文献信息

• [EN] NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ANTAGONISTES SÉLECTIFS DU RÉCEPTEUR NK-3, COMPOSITION PHARMACEUTIQUE ET MÉTHODES POUR UNE UTILISATION DANS DES TROUBLES À MÉDIATION PAR DES RÉCEPTEURS NK-3
  申请人：EUROSCREEN SA

  公开号：WO2011121137A1

  公开（公告）日：2011-10-06

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及公式I的新化合物及其作为治疗化合物的用途。
• NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS
  申请人：Euroscreen S.A.

  公开号：US20130023530A1

  公开（公告）日：2013-01-24

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及一种新型化合物I的使用作为治疗化合物。
• 3-Aryl-5-pyrazole-carboxylic-acid derivatives, their preparation and pharmaceutical compositions
  申请人：ELI LILLY AND COMPANY

  公开号：EP0112623A2

  公开（公告）日：1984-07-04

  Pyrazole derivatives of formula (I): wherein R' is hydrogen or methyl; Ar is pyridyl, thienyl, or optionally substituted phenyl; X is NH2, H, OH, halogen or C1-3 alkyl; and R is OH, OM, O-alk, NH2, NH-alk, N(alk)2 or N-alken-N-(alk)2; wherein alk is C1-5 alkyl; alken is (CH2)2 or (CH2)3 and M is a non-toxic cation; are useful in lowering blood urate levels in mammals.

  式 (I) 的吡唑衍生物： 其中 R' 是氢或甲基；Ar 是吡啶基、噻吩基或任选取代的苯基；X 是 NH2、H、OH、卤素或 C1-3 烷基；R 是 OH、OM、O-alk、NH2、NH-alk、N(alk)2 或 N-烯-N-(alk)2；其中烷是 C1-5 烷基；烯是 (CH2)2 或 ( )3，M 是无毒阳离子。
• NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
  申请人：Ogeda SA

  公开号：US10065960B2

  公开（公告）日：2018-09-04

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及式 I 的新型化合物 及其作为治疗化合物的用途。
• Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US11304929B2

  公开（公告）日：2022-04-19

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

  本发明包括式（I）化合物（其中基团 R1 至 R、A1 至 A4 和 n 具有权利要求书和说明书中给出的含义）、其作为 PHGDH 抑制剂的用途、含有此类化合物的药物组合物以及其作为药物的用途，特别是作为治疗和/或预防肿瘤疾病的药物。